The FDA has granted approval to Stealth’s Barth syndrome therapy, marking the first mitochondria-targeted treatment option for this rare genetic disorder. Barth syndrome primarily affects cardiac and skeletal muscle function due to mitochondrial abnormalities. Stealth’s therapeutic advance represents a significant milestone in addressing this previously untreatable condition, offering new hope for patients and families. The approval underscores the growing emphasis on mitochondrial medicine in rare diseases.